Stockscreener 앱 받기
1.535
0.99%
0.015
시간 외 거래:
1.50
-0.035
-2.28%
전일 마감가:
$1.52
열려 있는:
$1.56
하루 거래량:
199.05K
Relative Volume:
0.69
시가총액:
$65.84M
수익:
$51.13M
순이익/손실:
$-93.80M
주가수익비율:
-0.6883
EPS:
-2.23
순현금흐름:
$-129.10M
1주 성능:
+2.33%
1개월 성능:
+0.33%
6개월 성능:
+27.92%
1년 성능:
-48.83%
1일 변동 폭
$1.48
$1.56
1주일 범위
$1.48
$1.56
52주 변동 폭
$0.89
$4.0695
Repare Therapeutics Inc Stock (RPTX) Company Profile
명칭
Repare Therapeutics Inc
전화
(857) 412-7018
주소
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.535 | 65.62M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-09 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 개시 | CapitalOne | Overweight |
| 2022-04-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-17 | 재개 | Goldman | Buy |
| 2021-09-23 | 개시 | Stifel | Buy |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2021-06-28 | 개시 | Guggenheim | Buy |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2020-10-28 | 개시 | Northland Capital | Outperform |
| 2020-07-14 | 개시 | Cowen | Outperform |
| 2020-07-14 | 개시 | Goldman | Neutral |
| 2020-07-14 | 개시 | Morgan Stanley | Overweight |
| 2020-07-14 | 개시 | Piper Sandler | Overweight |
모두보기
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
Is Repare Therapeutics Inc. still worth holding after the dipFree AI-Powered Trade Planning with Indicators - Newser
Will Repare Therapeutics Inc. benefit from macro trendsDay Trading Plan with Entry Risk Management - Newser
Analyzing recovery setups for Repare Therapeutics Inc. investorsFree Smart Trend Trading with Weekly Signals - Newser
Repare Therapeutics Reports Q2 2025 Results and Strategic Moves - TipRanks
Repare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Repare Therapeutics Reports Q2 Earnings: Strategic Moves and Upcoming Data Releases - AInvest
Repare 2025 Q2 Earnings Strong Improvement as Net Loss Narrows 51.8% - AInvest
Repare Therapeutics Cuts Losses And Snags New Licensing Deals - Finimize
Repare Therapeutics Narrows Losses And Seeks New Paths Forward - Finimize
Repare (RPTX) Q2 Loss Narrows 52% - AOL.com
Repare Therapeutics' Strategic Shift and Milestone-Driven Outlook - AInvest
Repare Therapeutics Announces Licensing Deal and Strategic Updates - TipRanks
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year - TipRanks
Repare Therapeutics Inc. SEC 10-Q Report - TradingView
Repare Therapeutics Q2 net loss narrows to $16.7 mln - MarketScreener
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | RPTX Stock News - GuruFocus
Repare Therapeutics reports Q2 2025 revenue $109.5 mln, cash & marketable securities. - AInvest
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - The Globe and Mail
Backtesting results for Repare Therapeutics Inc. trading strategiesStrategy Builder for Growth Focused Traders - Newser
Predicting Repare Therapeutics Inc. trend using moving averagesChart Scanner for Swing Trade Timing - Newser
Is Repare Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSafe Investment Ideas with Growth Upside - Newser
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Daily Profit Focused Stock Screener - Newser
Can Repare Therapeutics Inc. hit a new high this monthFree Low Risk Swing Trade Opportunity List - Newser
Is Repare Therapeutics Inc. forming a reversal patternEntry and Exit Strategy for Swing Traders - Newser
Quantitative breakdown of Repare Therapeutics Inc. recent movePredicted Market Direction Based on Momentum - Newser
What makes Repare Therapeutics Inc. stock price move sharplyUnlock market-leading stock analysis - Jammu Links News
Should I hold or sell Repare Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
Repare Therapeutics Inc. Stock Analysis and ForecastAchieve rapid wealth accumulation with smart picks - Jammu Links News
How volatile is Repare Therapeutics Inc. stock compared to the marketMaximize portfolio value with smart investment plans - Jammu Links News
When is Repare Therapeutics Inc. stock expected to show significant growthAmplify your gains with low-risk picks - Jammu Links News
Does Repare Therapeutics Inc. stock perform well during market downturnsMaximize returns with data-driven strategies - Jammu Links News
Is Repare Therapeutics Inc. a growth stock or a value stockUnlock your portfolio’s hidden potential - Jammu Links News
How many analysts rate Repare Therapeutics Inc. as a “Buy”Capitalize on momentum stocks before they peak - Jammu Links News
How does Repare Therapeutics Inc. compare to its industry peersCapitalize on fast-moving trading opportunities - Jammu Links News
Is Repare Therapeutics Inc. a good long term investmentUnlock powerful market insights for success - Jammu Links News
How does Repare Therapeutics Inc. generate profit in a changing economyGet ahead with breakthrough trading ideas - Jammu Links News
What are Repare Therapeutics Inc. company’s key revenue driversBuild wealth steadily with proven strategies - Jammu Links News
Why is Repare Therapeutics Inc. stock attracting strong analyst attentionInvest in stocks with strong fundamentals - Jammu Links News
Repare Therapeutics (RPTX) to Release Quarterly Earnings on Tuesday - MarketBeat
Head to Head Comparison: Repare Therapeutics (NASDAQ:RPTX) and Provectus Biopharmaceuticals (OTCMKTS:PVCT) - Defense World
Repare Therapeutics Inc (RPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):